Revenue was in line with analyst estimates. Earnings per share (EPS) missed analyst estimates. Looking ahead, revenue is ...

GSK plc (LON:GSK – Get Free Report) insider Jonathan Symonds bought 7,150 shares of the stock in a transaction dated ...

U.K. stocks were lower after the close on Wednesday, as losses in the Pharmaceuticals & Biotech, Beverage and Fixed Line ...

Investing.com – United Kingdom equities were higher at the close ... declined 1.72% or 11.80 points to end at 676.40 and GSK plc (LON:GSK) down 1.66% or 25.00 points to 1,480.00.

GSK CEO Emma Walmsley's bet on blockbuster RSV vaccine, Arexvy, has hit a snag in recent months after the U.S. public health ...

The UK's FTSE 100 fell to an over two-month low on Wednesday, dragged down by the healthcare sector, while midcap stocks got a lift even as the latest UK budget came with the biggest tax increases in ...

Equities research analysts at Zacks Research decreased their FY2025 earnings per share (EPS) estimates for GSK in a research report issued to clients and investors on Wednesday, October 16th. Zacks ...

GSK GSK0.31%increase; green up pointing triangle shares topped the Stoxx Europe 600 index on Thursday after the pharmaceutical company agreed to pay up to $2.2 billion to settle thousands of U.S ...

GSK has agreed to pay up to $2.2 billion to settle most lawsuits in US state courts claiming that a discontinued version of the heartburn drug Zantac caused cancer, the company announced on ...

Roula Khalaf, Editor of the FT, selects her favourite stories in this weekly newsletter. Zantac may have been a heartburn medicine but it caused one almighty headache for GSK chief executive Emma ...

GSK GSK1.94%increase; green up pointing triangle agreed to pay more than $2 billion to settle almost all remaining liability cases in the U.S. over allegations its discontinued heartburn medicine ...